The agreement marks an intriguing partnership, with Ketchum's healthcare unit hoping it can boost its ability to serve healthcare clients as well as potentially impact when the agency is brought into the proceedings, according to Lorraine Thelian, senior partner at Ketchum. And with more clinical trials occurring outside of the U.S., Ketchum's international reach could strengthen MMG's offerings. MMG has expertise in oncology, endocrinology/cardiology, the central nervous system, as well as infectious and rare diseases.
“We're thrilled because obviously they are at the beginning of the healthcare pipeline in terms of when we have access to information,” Thelian said. “It's very important in understanding how to communicate to the patient audience as well as other groups crucial to drug development and safety.”
The Ketchum healthcare leadership team will remain in place, and MMG CEO John Benbrook will continue to lead his company, with a seven-member executive committee continuing to report to him.